丙型肝炎病毒（HCV）与人类嗜T淋巴细胞病毒1型（HTLV-1）合并感染患者中抗人类嗜T淋巴细胞病毒1型包膜蛋白Gp46抗体
Antibody to the human T-lymphotropic virus type 1 (HTLV-1) envelope protein Gp46 in patients co-infected with HCV and HTLV-1.
作者信息
Takeoka Hiroaki, Furusyo Norihiro, Toyoda Kazuhiro, Murata Masayuki, Sagara Yasuko, Kashiwagi Seizaburo, Hayashi Jun
机构信息
Department of Environmental Medicine and Infectious Diseases, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
出版信息
Am J Trop Med Hyg. 2007 Jul;77(1):192-6.
Human T-lymphotropic virus type 1 (HTLV-1) infection is known to affect hepatitis C virus (HCV) clearance and to accelerate the development of hepatocellular carcinoma in HCV-infected patients. In this study, we found the prevalence and titer of an antibody recognizing the central region of the HTLV-1 Gp46 protein to be associated with the severity of chronic liver disease. The antibody prevalence was significantly correlated with the stage of chronic liver disease (P < 0.0001): 3 (14.3%) of 21 patients with minimal-mild chronic hepatitis, 12 (24%) of 50 with moderate-severe chronic hepatitis, 7 (87.5%) of 8 with liver cirrhosis, and 13 (100%) of 13 with hepatocellular carcinoma. These results indicate that the antibody may be a useful marker of the deterioration of liver disease in patients co-infected with HCV and HTLV-1. This antibody may be useful for the diagnosis of liver diseases and the development of more effective treatments.
已知人类嗜T淋巴细胞病毒1型（HTLV-1）感染会影响丙型肝炎病毒（HCV）清除，并加速HCV感染患者肝细胞癌的发展。在本研究中，我们发现识别HTLV-1 Gp46蛋白中央区域的抗体的流行率和滴度与慢性肝病的严重程度相关。抗体流行率与慢性肝病分期显著相关（P < 0.0001）：21例轻度慢性肝炎患者中有3例（14.3%），50例中度至重度慢性肝炎患者中有12例（24%），8例肝硬化患者中有7例（87.5%），13例肝细胞癌患者中有13例（100%）。这些结果表明，该抗体可能是HCV和HTLV-1合并感染患者肝病恶化的有用标志物。这种抗体可能有助于肝病的诊断和更有效治疗方法的开发。
Zotero 插件